CD40LG and COVID-19: We analyzed the distribution of the cellular and humoral response in 51 COVID-19 patients, 94.1% had cellular and humoral immune response to SARS-CoV-2 detected by all three methods: IFN-γELISpot, CoVITEST and antibody detection by Luminex (IgG, IgA or IgM); 100% had a cellular immune response to SARS-CoV-2 by IFN-γELISpot and CoVITEST (sensitivity 100%) and, finally, 94.1% had cellular and a humoral immune response to SARS-CoV-2 by CoVITEST and Luminex (Figure 4).